The application of etanercept, a drug neutralizing tumor necrosis factor-α and inflammatory cytokines (28), in experimental settings on OSA-afflicted obese males led to a significant attenuation of daytime sleepiness. This evidence concerns the gene TNF and obstructive sleep apnea syndrome.